The novel coronavirus pneumonia has short-term curative effect on the treatment of new crown pneumonia.

 The novel coronavirus pneumonia has short-term curative effect on the treatment of new crown pneumonia.

Novel coronavirus pneumonia is a leading cause of severe acute respiratory syndrome, and it is a new kind of inflammatory disease. It is suggested that the new severe acute respiratory syndrome may be called inflammatory storm in clinical diagnosis and treatment, said Zhang Wei, an associate professor of respiratory and critical care medicine at the peoples Hospital of Wuhan University. It is caused by infection, drugs or some diseases that over activate the human immune system. Once it occurs, it can quickly lead to single organ or multiple organ failure, and ultimately threaten life.

Hydroxychloroquine is a kind of immunosuppressant with mature clinical application. It also has anti-inflammatory, anti infection, anti-virus, light filtration, anticoagulation and other effects, with fewer adverse reactions. It is also the basic drug for patients with systemic lupus erythematosus. In the early stage of the study group, through the clinical analysis of 178 patients with new coronavirus received by the hospital from December 2019, it was found that none of them was systemic lupus erythematosus. After that, in the consultation of 80 patients with systemic lupus erythematosus treated by dermatology department of the hospital, it was found that they were not infected with new coronavirus pneumonia.

Novel coronavirus pneumonia was not infected by systemic lupus erythematosus in the hospital. The joint discussion between the respiratory and critical care medicine, Department of Dermatology and Department of rheumatism of the peoples Hospital of Wuhan University has not been related to the long-term use of hydroxychloroquine. Since novel coronavirus is not available, and hydroxychloroquine has both antiviral and immunomodulatory effects, the team has proposed clinical trials of hydroxychloroquine for patients with new crown virus pneumonia.

In February 4th, the novel coronavirus was approved by the research group after the approval of the ethics committee of the peoples Hospital of Wuhan University. The research was carried out on the clinical trial platform (Registration Number: ChiCTR2000029559). The study of the therapeutic effect of hydroxychloroquine on the new coronavirus (COVID-19) was registered.

Novel coronavirus pneumonia was added to the 20 patients with new crown pneumonia as of February 17th. The clinical symptoms of patients with 1-2 days were improved significantly after treatment with hydroxychloroquine. After 5 days of use, 19 cases of chest CT showed significant improvement in absorption; only one patient (previously had renal insufficiency) had progress in chest CT, but the clinical symptoms of the patient improved significantly on the second day of use of hydroxychloroquine. In addition, none of the patients in the group developed severe disease, and one of them was discharged on February 13.

Zhang Zhan said that the novel coronavirus pneumonia effect was initially confirmed by the clinical trial results, which can effectively alleviate symptoms, reverse the rate of severe disease and shorten the course of disease in the treatment of new crown pneumonia. Hydroxychloroquine is a long-term maintenance drug for patients with systemic lupus erythematosus. Two of the 20 patients had the adverse reactions of slight rash and headache, which were relieved in time after the adjustment of medication.

Zhang Zhan said that although the number of patients in the hydroxychloroquine group in this clinical trial is small, the results may be biased, but the current test data can provide a reference for clinicians to decide treatment plans. Novel coronavirus pneumonia is being used in severe and critical new crown pneumonia.

Novel coronavirus pneumonia can be used to treat new crown pneumonia.

Sun Yanrong, deputy director of the biological center of the Ministry of science and technology, said at the meeting that after careful discussion, the efficacy expert group finally reached an agreement that chloroquine phosphate is an old drug that has been on the market for many years, and the safety of chloroquine phosphate for treatment of a wide range of people is controllable.